. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Cytotherapy. 2014 Sep;16(9):1280–1293. doi: 10.1016/j.jcyt.2014.05.025

Table II. Up-regulation of CXCR4 receptors on HSCs prior to IUHSCT.

Group 3. DFX-treated CD34⁺ engraftment without plerixafor, with prior MSC and CD34⁺ transplantation				Group 4. DFX-treated CD34⁺ engraftment with plerixafor, with prior MSC and CD34⁺ transplantation
	Surgery 1 Day 62	Surgery 2 Day 76	Human Cells in PB (%)	Sheep no.	Surgery 1 Day 62	Surgery 2 Day 76	Human Cells in PB (%)
2795	4,000,000 MSC 120,000 CD34⁺	170,000 CD34⁺	2.35	2797	4,000,000 MSC 300,000 CD34⁺	750,000 CD34⁺	27.53
2796	4,000,000 MSC 120,000 CD34⁺	170,000 CD34	1.70	2798	4,000,000 MSC 70,000 CD34⁺	110,000 CD34⁺	3.44
				2799	4,000,000 MSC 70,000 CD34⁺	110,000 CD34⁺	4.90
				2800	4,000,000 MSC 89,000 CD34⁺	120,000 CD34⁺	2.35
				2801	4,000,000 MSC 89,000 CD34⁺	120,000 CD34⁺	2.50
Median			2.03	Median			3.44
Standard deviation			0.42	Standard deviation			10.88

Fetal sheep were transplanted with cord blood-derived CD34⁺ cells with or without plerixafor treatment two weeks after cotransplanting bone marrow-derived MSCs and CD34⁺ cells from the same cord blood unit. Cells for surgery 2 were incubated with deferoxamine overnight prior to transplantation. Peripheral blood was collected for analysis at 8 weeks post-transplantation for Group 3 and at 10 weeks post-transplantation (during gestation) for Group 4. Multi-lineage human hematopoietic engraftment in the peripheral blood was assayed as described in methods.